We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
16 Aug 2021 - 26 Aug 2021
Virtual Venue

CtDNA Analysis Assesses Early Relapse Detection in Colorectal Cancer

By LabMedica International staff writers
Posted on 17 Jun 2021
Print article
Image: Schematics of how the Signatera bespoke mPCR NGS assay works (Photo courtesy of Natera)
Image: Schematics of how the Signatera bespoke mPCR NGS assay works (Photo courtesy of Natera)
Colorectal cancer (CRC) is a type of cancer that begins in the large intestine (colon). The colon is the final part of the digestive tract. Colon cancer typically affects older adults, though it can happen at any age. It usually begins as small, noncancerous (benign) clumps of cells called polyps that form on the inside of the colon. Over time some of these polyps can become colon cancers.

Challenges in the postoperative management of stage III CRC include selection of high-risk patients for adjuvant chemotherapy (ACT), lack of markers to assess ACT efficacy, assessment of recurrence risk after ACT, and, lack of markers to guide treatment decisions for high-risk patients e.g. additional therapy or intensified surveillance. Circulating tumor DNA (ctDNA) is a promising marker with potential to mitigate the challenges.

Medical Scientists from Aarhus University Hospital (Aarhus, Denmark) collected blood samples from 166 stage III CRC patients treated with curative intent at Danish and Spanish hospitals in 2014-2019. There were 1, 227 blood samples were collected prior to and immediately after surgery, and every third month for up to 36 months. Per patient 16 personal mutations were used to quantify plasma ctDNA, using the Signatera, bespoke mPCR NGS assay Natera, Austin, TX, USA).

The team reported that detection of ctDNA was a strong recurrence predictor, both postoperatively (Hazard ratio [HR] = 7.2), directly after ACT (HR = 18.2), and when measured serially after end of treatment (HR = 41). The recurrence rate of postoperative ctDNA positive patients treated with ACT was 80% (16/20). Patients who stayed ctDNA positive during ACT, all recurred. Serial post-treatment ctDNA measurements revealed exponential growth for all recurrence patients following either a SLOW (26% increase/month) or a FAST (126% increase/month) pattern.

From ctDNA detection to radiologic recurrence, ctDNA levels of FAST patients increased by a median 117-fold, and up to 554-fold. The 3-year overall survival was 43% for FAST patients and 100% for SLOW and non-recurrence patients (HR = 41.3). Coinciding CT scans and ctDNA measurements (n = 113 patients, 235 coinciding events, median 2 per patient) showed a high agreement (92%) and ctDNA either detected residual disease before the CT scan (n = 7 patients) or at the same time (n = 14 patients). The median lead-time was 7.5 months.

The authors concluded they had confirmed the prognostic power of serial postoperative ctDNA analysis. Moreover, it provided novel analyses demonstrating that ctDNA is more sensitive for recurrence detection than CT scans and can be used for tumor growth rate assessments. The difference between FAST and SLOW growing tumors suggest that growth rates could guide whom to start on systemic therapy rapidly and whom to send for diagnostic imaging. The study was presented at the 2021 ASCO Annual Meeting held June 4-8, 2021.

Related Links:
Aarhus University Hospital
Natera


Gold Supplier
COVID-19 RT-PCR Kit
CoviPath COVID-19 RT-PCR Kit
New
Silver Supplier
Sample-to-Result COVID Testing Platform
LabTurbo AIO Sample-to-Result COVID Testing Platform
New
COVID-19 POC Test
FREND COVID-19 SP
New
SARS-CoV-2 Real-Time RT-PCR Test
GB SARS-CoV-2 Real-Time RT-PCR [E/N/ORF1ab (RdRp)]

Print article

Channels

Industry

view channel
Illustration

ELITechGroup Acquires Freezing Point Osmometry Provider GONOTEC

ELITechGroup (Puteaux, France) has acquired GONOTEC (Berlin, Germany), thus uniting two osmometry market leaders. The acquisition will also provides the industry with a full range of osmometry solutions... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.